New research indicates that people who stop using popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Findings released in a major medical journal shows that while overweight individuals frequently drop about a fifth of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such medications should be informed of the potential of fast rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment mass in about one and a half years.
Comparing Treatments
The analysis, which reviewed dozens of trials involving thousands of participants, compared the outcomes of the injectable medications with older methods.
Researchers point out that individuals who shed pounds through lifestyle changes alone typically experience a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Nutrition scientists propose the mechanism of the jabs explains the heightened rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating much more probable."
A Chronic Issue?
Health authorities recommend the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals contend that, considering the significant potential of weight regain, the treatment is often ongoing.
This view is reinforced by drug manufacturers, who note that the results "underscore the long-term nature of obesity," similar to managing conditions like diabetes.
Patient Testimonies
Users who have stopped the medication describe a powerful return of appetite.
"I experienced something flipping and you're instantly starving," described one woman.
This challenge is compounded if users have not adopted lasting dietary or behavioural modifications during therapy.
Growing Adoption
Recent estimates show that millions of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, clinicians emphasize that while the jabs are powerful agents for shedding pounds, they are not a standalone cure and lasting health benefits hinges on integrated lifestyle management.
